Verastem Reports Positive Initial Trial Data and Prices Offering
Verastem Oncology said its in-development tumor treatment VS-7375 showed clinical activity and a favorable safety and tolerability profile across multiple dose levels and tumor types. The company also priced an underwritten offering.
Verastem Oncology reported positive initial efficacy findings from a trial of its investigational tumor treatment, VS-7375. The company said the treatment showed robust clinical activity and a favorable safety and tolerability profile across multiple dose levels and tumor types.